Kyorin may be among potential Japan partners for Cipla
This article was originally published in Scrip
A knowledgeable source has informed Scrip that the Indian firm Cipla has initiated preliminary discussions with the Kyorin group of Japan for a potential alliance, with an eye on opportunities in the generics space. With its management succession plan in place (scripintelligence.com, 7 February 2013) and a renewed business thrust on globalization through alliances or on-the-ground presence, Cipla now appears to be setting its sights on the world's second largest pharmaceutical market. The source stressed that discussion are still at an early stage and that Cipla may also be speaking with other potential partners.
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.